RET fusion-positive NSCLC
Oncology · 2023–2023
1decision
1medicine
1carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| selpercatinib Locally advanced or metastatic RET fusion-positive non-small cell lung cancer (NSCLC), irrespective of line of therapy. | Jul 2023 | Not recommended | 1 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.